Improving the Therapeutic Index of Proinflammatory Cytokines for Cancer Immunotherapy Werewolf Therapeutics, Inc., is an ...

Compass Therapeutics' tovecimig shows promise in biliary cancer, boasting a 17.1% response rate. Despite high risks, I ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable responses to existing therapies. While standard ...

Positive phase 3 results from the CAN-2409 clinical trial in intermediate-to-high risk localized prostate cancer have been ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD-1/L1 therapySEED's first-in-class RBM39 degrader, reported ...

As excitement builds around personalized cancer vaccines, researchers at the Icahn School of Medicine at Mount Sinai have ...

Houston, Texas and Tuebingen, Germany, May 13, 2025 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development of T ...

Welcome to the Relmada Therapeutics first-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference is being recorded, and will be available for replay on the location website ...

Neurological disorders, including neurosurgical conditions and various neurological diseases, are often associated with ...

Wall Street stocks jumped on Monday with all three benchmark indices back above pre-Liberation Day levels after the US and ...